Loading
A phase 1 trial of ATX-559 run by Accent Therapeutics, terminated.
First-in-Human Study of ATX-559, an Oral Inhibitor of DHX9, in Patients With Advanced or Metastatic Solid Tumors, and Molecularly Defined Cancers is a phase 1 interventional study registered as NCT06625515 by Accent Therapeutics, with 17 participants enrolled, started 2024-10-11. Conditions recorded: Advanced Solid Tumors, Breast Cancer Recurrent, Colorectal Cancer Metastatic, Colon Cancer, Rectal Adenocarcinoma and Endometrial Cancer. Interventions recorded: ATX-559.
Shares Accent Therapeutics, Breast cancer (all types), Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Accent Therapeutics, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Endometrial cancer, Breast cancer (all types), Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Endometrial cancer, Breast cancer (all types), Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Endometrial cancer, Breast cancer (all types), Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Breast cancer (all types), Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Breast cancer (all types), Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Endometrial cancer, Metastatic cancer (cancer that has spread) and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/